Co-Existing Myeloid Mutations at Diagnosis Are Associated With Increased Tyrosine Kinase Inhibitor Utilization in Chronic Phase CML (SOHO 2026) - Sep 1, 2026 - Abstract #CML-709; Location: LEVEL 3, HALL B3; "Imatinib exposure was more common in the mutation-positive cohort (83.3% vs 60.2%; P = 0.03), and all imatinib-exposed mutation-positive patients discontinued imatinib compared with 81.3% of mutation-negative patients (P = 0.04). Use of ponatinib, a third-generation TKI often reserved for resistant or high-risk disease, was also significantly higher among mutation-positive patients (41.7% vs 13.5%; P < 0.001). Patients with co-existing myeloid mutations appeared to experience a more complex therapeutic course characterized by increased TKI switching and need for later-generation TKIs. ASXL1: additional sex combs like 1; BCR::ABL1: breakpoint cluster region:: ABL proto-oncogene 1; DNMT3A: DNA methyltransferase 3 alpha); IQR: interquartile range; MMR: major molecular response; TKI: tyrosine kinase inhibitor; TET2: tet methylcytosine dioxygenase 2; TP53: tumor protein p53."
Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • ASXL1 • BCR • DNMT3A • TET2 • TP53
|
|
Umar Iqbal 1; Akriti Jain 2; Tod Knepper 1; Jinming Song 1; Ling Zhang 1; Rory Shallis 1; Andrew Kuykendall 1; Seongseok Yun 1; Sam B Reynolds 1; Alison RWalker 1; Jeffrey Lancet 1; Rami Komrokji 1; David Sallman 1; Eric Padron 1; Javier Pinilla 1; Onyee Chan 1; Kendra Sweet 1; Zhuoer Xie 1
|